ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)

PHASE2UnknownINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

July 31, 2019

Study Completion Date

December 31, 2020

Conditions
Uveitis
Interventions
DRUG

ACTH gel

Starting at month 6, retreatment will be offered to study subjects who have demonstrated any level of response during the first 6 months and who meet any of these Retreatment Criteria listed below. Patients receiving retreatment will receive the dose that was assigned to them at randomization.

Trial Locations (2)

90017

RECRUITING

Retina Vitreous Associates, Medical Group, Los Angeles

94303

NOT_YET_RECRUITING

Stanford University, Palo Alto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mallinckrodt

INDUSTRY

lead

Quan Dong Nguyen

OTHER